PLX Share Price Performance

PLX Community Fair Values

ZW
Zwfis
Community Contributor
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%.
US$4.23
FV
65.7% undervalued intrinsic discount
14.00%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
3 months ago author updated this narrative
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Pipeline Advancements Will Unlock Global Therapeutic Potential
Key Takeaways Expansion of rare disease therapeutics and strategic partnerships support robust product pipeline growth, diversified revenue streams, and improved commercial momentum. Regulatory incentives and a cost-efficient production platform enhance margins, accelerate market entry, and strengthen long-term earnings potential.
US$14.00
FV
89.6% undervalued intrinsic discount
40.40%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
23users have followed this narrative
10 days ago author updated this narrative

View all narratives

Recent PLX News & Updates

No updates

Protalix BioTherapeutics, Inc. Key Details

Last Reported Earnings

Mar 31, 2025

Next Reporting Earnings

n/a

Earnings per share (EPS): 0.049
Gross Margin: 49.97%
Net Profit Margin: 6.54%
Debt/Equity Ratio: 0%

View full report ›

Protalix BioTherapeutics, Inc. Competitors

View more competitors

About PLX

Founded: n/a
Employees: 213
CEO: Dror Bashan
WebsiteView website: www.protalix.com

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.

U.S. Market Performance

7 Days: -2.7%
3 Months: 10.1%
1 Year: 17.7%
Year to Date: 5.9%

In the last week, the market has fallen 2.7%, dragged down most by the Financials. In the last year, the market is actually up 18%. Looking forward, earnings are forecast to grow by 15% annually. Market details ›

💥 How Agentic AI Could Change Every Industry

Richard Bowman

August 2025

This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.

Last Week

Protalix BioTherapeutics Stock Price